Kynurenine administered together with probenecid markedly inhibits pentylenetetrazol-induced seizures. An electrophysiological and behavioural study

Németh, Hajnalka; Robotka, Hermina; Kis, Zsolt; Rózsa, Éva; Janáky, Tamás; Somlai, Csaba; Marosi, Máté; Farkas, Tamás; Toldi, József; Vécsei, László

doi:10.1016/j.neuropharm.2004.06.007

Cited by 51 publications

(23 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Differences between the amplitudes were determined statistically (Paired t-test, with the P value set at 0.05 for significance), likewise in our earlier publications (Nemeth et al, 2004;Robotka et al, 2005).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Hippocampal (CA1) activities in Wistar rats from different vendors

Marosi

Rákos

Robotka

et al. 2006

Journal of Neuroscience Methods

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

“…Moreover, this model proved to be sensitive enough to follow the physiological status of the CA1 region of hippocampus (Nemeth et al, 2004;Robotka et al, 2005).…”

Section: Introductionmentioning

confidence: 97%

Hippocampal (CA1) activities in Wistar rats from different vendors

Marosi

Rákos

Robotka

et al. 2006

Journal of Neuroscience Methods

View full text Add to dashboard Cite

“…in the range of normal, ambient KYNA levels in the mammalian brain (Schwarcz and Pellicciari, 2002). In experimental animals, comparatively minor increases in brain KYNA are neuroprotective against ischemic insults (Cozzi et al, 1999), exert anticonvulsant effects (Chiarugi et al, 1995;Nemeth et al, 2004;Pellicciari et al, 1994), affect the firing pattern of dopaminergic and noradrenergic neurons in the midbrain (Erhardt et al, 2001b;Nilsson et al, 2005), and reduce the extracellular levels of glutamate, dopamine and acetylcholine in the striatum (Carpenedo et al, 2001;Potter et al, 2005;Rassoulpour et al, 2005). Conversely, reductions in brain KYNA augment neuronal vulnerability to NMDA receptor-mediated excitotoxic insults (Sapko et al, 2006), enhance a7nACh receptor function (Alkondon et al, 2004), and cause an elevation of extracellular dopamine levels (Wu et al, in press).…”

Section: Introductionmentioning

confidence: 99%

Astrocytic localization of kynurenine aminotransferase II in the rat brain visualized by immunocytochemistry

Guidetti

Hoffman

Meléndez-Ferro

et al. 2006

Glia

125

111

View full text Add to dashboard Cite

Kynurenic acid (KYNA), a metabolite of the kynurenine pathway of tryptophan degradation, is a neuroinhibitory agent present in the mammalian brain. Endogenous KYNA preferentially affects the alpha7 nicotinic acetylcholine (alpha7nACh) receptor and, possibly, the glycine co-agonist (glycineB) site of the NMDA receptor. Functionally relevant fluctuations in brain KYNA occur under both physiological and pathological conditions, affecting cholinergic and glutamatergic neurotransmission. Kynurenine aminotransferase II (KAT II), the major biosynthetic enzyme of KYNA in the rat brain, catalyzes the irreversible formation of KYNA from its immediate bioprecursor, kynurenine. We now purified rat kidney KAT II to homogeneity, generated a polyclonal rabbit anti-rat KAT II antibody, and purified the antibody using routine biochemical methods. The antibody selectively recognized KAT II by Western blot analysis and in immunotitration experiments. Used for immunocytochemistry, the antibody revealed discrete, specific staining of KAT II-positive astrocyte-like cells throughout the adult rat brain. The presence of KAT II in astrocytes was confirmed by double fluorescence immunostaining with an antibody against the astrocyte-specific marker glial fibrillary acidic protein (GFAP). No specific labeling was detected in neurons or microglia. However, KAT II-positive astrocytes were intimately associated with select neuron populations, supporting a neuromodulatory role of KYNA. Intense staining was frequently seen around brain capillaries, with astrocytic end feet contacting the capillary wall. This may explain the rapid access of blood-derived kynurenine to KAT II-containing astrocytes. The new anti-KAT II antibody should be useful in the further elucidation of the presumed role of KYNA in brain physiology and pathology.

show abstract

“…Group II Control (Haloperidol 1 mg/kg, i.p) [21] Group III Kynurenic acid (50 mg/kg, i.p) Group IV Kynurenic acid (100 mg/kg, i.p) [22] Group V Levodopa (150 mg/kg, i.p) [21] comparison test were used to test the significance of the difference between the variables in various groups. P < 0.05 was considered to be statistically significant.…”

Section: Groups Treatmentsmentioning

confidence: 99%

Untitled

Aamir¹

2017

IJGP

View full text Add to dashboard Cite

Aim: The objectives of the present research were ssto observe the effect of N-methyl-D-aspartate (NMDA) receptor antagonist on Parkinson model(s) in rats and to compare the efficacy of NMDA receptor antagonist with standard antiparkinson drug. Materials and Methods: Albino rats were divided into five experimental groups of six each. 24 animals except normal and acute dose of haloperidol (1 mg/kg) were administered intraperitoneally for induction of catalepsy. Six animals received saline 0.9% NaCl and served as normal saline. On the 20 th day, catalepsy was evaluated by reported instruments. Levodopa (150mg/kg) was used as standard drug and kynurenic acid (50 mg/kg and 100 mg/kg) was used as test drug. Different instrument utilized in the study was catalepsy bar test, actophotometer, and rotarod. Results and Discussions: The results showed that acute administration of kynurenic acid (50 mg/kg and 100 mg/kg) significantly reduced catalepsy, grooming and significantly increased motor coordination, locomotor activity. Conclusion: It was concluded from the study that kynurenic acid ameliorates the symptoms of Parkinson's disease in rats.

show abstract

Kynurenine administered together with probenecid markedly inhibits pentylenetetrazol-induced seizures. An electrophysiological and behavioural study

Cited by 51 publications

References 36 publications

Hippocampal (CA1) activities in Wistar rats from different vendors

Hippocampal (CA1) activities in Wistar rats from different vendors

Astrocytic localization of kynurenine aminotransferase II in the rat brain visualized by immunocytochemistry

Untitled

Contact Info

Product

Resources

About